150 related articles for article (PubMed ID: 15322424)
1. Molecular detection of dopamine decarboxylase expression by means of reverse transcriptase and polymerase chain reaction in bone marrow and peripheral blood: utility as a tumor marker for neuroblastoma.
Bozzi F; Luksch R; Collini P; Gambirasio F; Barzanò E; Polastri D; Podda M; Brando B; Fossati-Bellani F
Diagn Mol Pathol; 2004 Sep; 13(3):135-43. PubMed ID: 15322424
[TBL] [Abstract][Full Text] [Related]
2. mRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high-risk disease when measured at diagnosis.
Träger C; Vernby A; Kullman A; Ora I; Kogner P; Kågedal B
Int J Cancer; 2008 Dec; 123(12):2849-55. PubMed ID: 18814238
[TBL] [Abstract][Full Text] [Related]
3. Clinical application of minimal residual neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction.
Kuroda T; Saeki M; Nakano M; Mizutani S
J Pediatr Surg; 1997 Jan; 32(1):69-72. PubMed ID: 9021573
[TBL] [Abstract][Full Text] [Related]
4. Detection of neuroblastoma cells in bone marrow and peripheral blood at diagnosis by the reverse transcriptase-polymerase chain reaction for tyrosine hydroxylase mRNA.
Miyajima Y; Kato K; Numata S; Kudo K; Horibe K
Cancer; 1995 Jun; 75(11):2757-61. PubMed ID: 7743482
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of tyrosine hydroxylase mRNA for diagnosis and detection of minimal residual disease in neuroblastoma.
Ito R; Asami S; Kagawa S; Motohashi S; Shichino H; Chin M; Yoshida Y; Nemoto N; Mugishima H; Suzuki T
Biol Pharm Bull; 2004 Mar; 27(3):315-8. PubMed ID: 14993794
[TBL] [Abstract][Full Text] [Related]
6. Detection procedures for neuroblastoma cells metastatic to blood and bone marrow: blinded comparison of chromogranin A heminested reverse transcription polymerase chain reaction to tyrosine hydroxylase nested reverse transcription polymerase chain reaction and to anti-GD2 immunocytology.
Pagani A; Macri L; Faulkner LB; Tintori V; Paoli A; Garaventa A; Bussolati G
Diagn Mol Pathol; 2002 Jun; 11(2):98-106. PubMed ID: 12045713
[TBL] [Abstract][Full Text] [Related]
7. Detection of neuroblastoma cells in blood by reverse transcriptase-polymerase chain reaction.
Gao Y; Li G; Zhang X; Xu Q; Zheng B
Chin Med J (Engl); 1997 May; 110(5):341-5. PubMed ID: 9594298
[TBL] [Abstract][Full Text] [Related]
8. TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients.
Yáñez Y; Hervás D; Grau E; Oltra S; Pérez G; Palanca S; Bermúdez M; Márquez C; Cañete A; Castel V
J Cancer Res Clin Oncol; 2016 Mar; 142(3):573-80. PubMed ID: 26498952
[TBL] [Abstract][Full Text] [Related]
9. Detection of the PGP9.5 and tyrosine hydroxylase mRNAs for minimal residual neuroblastoma cells in bone marrow and peripheral blood.
Yanagisawa TY; Sasahara Y; Fujie H; Ohashi Y; Minegishi M; Itano M; Morita S; Tsuchiya S; Hayashi Y; Ohi R; Konno T
Tohoku J Exp Med; 1998 Mar; 184(3):229-40. PubMed ID: 9591338
[TBL] [Abstract][Full Text] [Related]
10. Real-time RT-PCR of tyrosine hydroxylase to detect bone marrow involvement in advanced neuroblastoma.
Pession A; Libri V; Sartini R; Conforti R; Magrini E; Bernardi L; Fronza R; Olivotto E; Prete A; Tonelli R; Paolucci G
Oncol Rep; 2003; 10(2):357-62. PubMed ID: 12579272
[TBL] [Abstract][Full Text] [Related]
11. Detection of neuroblastoma cells during clinical follow up: advanced flow cytometry and rt-PCR for tyrosine hydroxylase using both conventional and real-time PCR.
Esser R; Glienke W; Bochennek K; Erben S; Quaiser A; Pieper C; Eggert A; Schramm A; Astrahantseff K; Hansmann ML; Schwabe D; Klingebiel T; Koehl U
Klin Padiatr; 2011 Nov; 223(6):326-31. PubMed ID: 22095188
[TBL] [Abstract][Full Text] [Related]
12. Minimal disease detection in peripheral blood and bone marrow from patients with non-metastatic neuroblastoma.
Yáñez Y; Grau E; Oltra S; Cañete A; Martínez F; Orellana C; Noguera R; Palanca S; Castel V
J Cancer Res Clin Oncol; 2011 Aug; 137(8):1263-72. PubMed ID: 21706131
[TBL] [Abstract][Full Text] [Related]
13. Quantitative analysis of tyrosine hydroxylase mRNA for sensitive detection of neuroblastoma cells in blood and bone marrow.
Träger C; Kogner P; Lindskog M; Ponthan F; Kullman A; Kågedal B
Clin Chem; 2003 Jan; 49(1):104-12. PubMed ID: 12507966
[TBL] [Abstract][Full Text] [Related]
14. Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR.
Wagner LM; Burger RA; Guichard SM; Raimondi SC; Santana VM; Furman WL; Barnette P; Danks MK
J Pediatr Hematol Oncol; 2006 Oct; 28(10):635-41. PubMed ID: 17023822
[TBL] [Abstract][Full Text] [Related]
15. ppGalNAc-T13: a new molecular marker of bone marrow involvement in neuroblastoma.
Berois N; Blanc E; Ripoche H; Mergui X; Trajtenberg F; Cantais S; Barrois M; Dessen P; Kågedal B; Bénard J; Osinaga E; Raguénez G
Clin Chem; 2006 Sep; 52(9):1701-12. PubMed ID: 16873292
[TBL] [Abstract][Full Text] [Related]
16. Sialyltransferase STX (ST8SiaII): a novel molecular marker of metastatic neuroblastoma.
Cheung IY; Vickers A; Cheung NK
Int J Cancer; 2006 Jul; 119(1):152-6. PubMed ID: 16450393
[TBL] [Abstract][Full Text] [Related]
17. Significance of molecular quantification of minimal residual disease in metastatic neuroblastoma.
Tchirkov A; Paillard C; Halle P; Bernard F; Bordigoni P; Vago P; Deméocq F; Kanold J
J Hematother Stem Cell Res; 2003 Aug; 12(4):435-42. PubMed ID: 12965080
[TBL] [Abstract][Full Text] [Related]
18. Sequential detection of tumor cells in the peripheral blood and bone marrow of patients with stage IV neuroblastoma by the reverse transcription-polymerase chain reaction for tyrosine hydroxylase mRNA.
Miyajima Y; Horibe K; Fukuda M; Matsumoto K; Numata S; Mori H; Kato K
Cancer; 1996 Mar; 77(6):1214-9. PubMed ID: 8635146
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications of minimal disease in the bone marrow and peripheral blood in neuroblastoma.
Shono K; Tajiri T; Fujii Y; Suita S
J Pediatr Surg; 2000 Oct; 35(10):1415-20. PubMed ID: 11051140
[TBL] [Abstract][Full Text] [Related]
20. Useful markers for detecting minimal residual disease in cases of neuroblastoma.
Ootsuka S; Asami S; Sasaki T; Yoshida Y; Nemoto N; Shichino H; Chin M; Mugishima H; Suzuki T
Biol Pharm Bull; 2008 Jun; 31(6):1071-4. PubMed ID: 18520032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
